Information

Related Research Units

Dana Farber Boston Childrens Cancer and Blood Disorders Center Research
Hematology and Oncology Research

Research Overview

Todd Golub's laboratory focuses on the genetic basis of cancer, with particular emphasis on the utilization of new genomics and computer science approaches to cancer diagnosis and treatment planning. The laboratory has pioneered the use of DNA microarrays, or 'DNA chips,' for cancer diagnosis and is currently extending these techniques to gain insight into the molecular basis of human cancer. Part of this research effort involves the integration of computer science experts into the research group to extract clinically meaningful patterns from complex genetic information within tumors.

 

Research Background

Todd Golub received his MD from the University of Chicago Pritzker School of Medicine. He competed an internship, residency, and fellowship at Children's Hospital Boston/Dana-Farber Cancer Institute. Todd is the recipient of multiple awards, including the 2009 AACR-Richard and Hinda Rosenthal Memorial Award, 2008 E. Mead Johnson Award from the Society for Pediatric Research, the 2007 Oski Prize of the American Society of Pediatric Hematology-Oncology, Discover Magazine’s Inventor of the Year (Health Category), the Daland Prize of the American Philosophical Society, the Outstanding Achievement Award from the American Association for Cancer Research, and the 2007 Paul Marks Prize for Cancer Research. Todd also serves on the Board of Scientific Advisors of the National Cancer Institute.

 

Publications

  1. SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO. Nature. 2025 Feb; 638(8052):1104-1111. View Abstract
  2. Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors. bioRxiv. 2025 Jan 25. View Abstract
  3. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024 10; 5(10):1479-1493. View Abstract
  4. Editor's Note: Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. Cancer Res. 2024 Aug 01; 84(15):2561. View Abstract
  5. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science. 2024 01 19; 383(6680):eadf2341. View Abstract
  6. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Mol Cell. 2024 Jan 18; 84(2):261-276.e18. View Abstract
  7. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature. 2023 Oct; 622(7984):850-862. View Abstract
  8. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal. Genome Biol. 2023 08 23; 24(1):192. View Abstract
  9. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906. View Abstract
  10. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. J Biol Chem. 2023 09; 299(9):105046. View Abstract
  11. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv. 2023 May 06. View Abstract
  12. Single duplex DNA sequencing with CODEC detects mutations with high sensitivity. Nat Genet. 2023 05; 55(5):871-879. View Abstract
  13. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08. View Abstract
  14. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. bioRxiv. 2023 Feb 04. View Abstract
  15. An intravenous DNA-binding priming agent protects cell-free DNA and improves the sensitivity of liquid biopsies. bioRxiv. 2023 Jan 14. View Abstract
  16. A nanoparticle priming agent reduces cellular uptake of cell-free DNA and enhances the sensitivity of liquid biopsies. bioRxiv. 2023 Jan 14. View Abstract
  17. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer Discov. 2022 12 02; 12(12):2880-2905. View Abstract
  18. Systematic profiling of conditional degron tag technologies for target validation studies. Nat Commun. 2022 09 20; 13(1):5495. View Abstract
  19. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022 08 01; 24(8):1352-1363. View Abstract
  20. Publisher Correction: DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022 Jul 12; 6(1):50. View Abstract
  21. Proceedings of the fifth international Molecular Pathological Epidemiology (MPE) meeting. Cancer Causes Control. 2022 Aug; 33(8):1107-1120. View Abstract
  22. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022 Apr 28; 6(1):30. View Abstract
  23. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022 06; 3(6):681-695. View Abstract
  24. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022 03 18; 375(6586):1254-1261. View Abstract
  25. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat Biomed Eng. 2022 03; 6(3):257-266. View Abstract
  26. Duplex-Repair enables highly accurate sequencing, despite DNA damage. Nucleic Acids Res. 2022 01 11; 50(1):e1. View Abstract
  27. Publisher Correction: A metastasis map of human cancer cell lines. Nature. 2021 Nov; 599(7885):E7. View Abstract
  28. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021 11; 2(11):1243. View Abstract
  29. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367. View Abstract
  30. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat Genet. 2021 08; 53(8):1196-1206. View Abstract
  31. Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. Cancer Discov. 2021 09; 11(9):2282-2299. View Abstract
  32. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Nat Cancer. 2021 04; 2(4):414-428. View Abstract
  33. A first-generation pediatric cancer dependency map. Nat Genet. 2021 Apr; 53(4):529-538. View Abstract
  34. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nat Biotechnol. 2021 06; 39(6):697-704. View Abstract
  35. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021 02; 590(7846):486-491. View Abstract
  36. Cancer research needs a better map. Nature. 2021 01; 589(7843):514-516. View Abstract
  37. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493. View Abstract
  38. A metastasis map of human cancer cell lines. Nature. 2020 12; 588(7837):331-336. View Abstract
  39. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun. 2020 08 27; 11(1):4296. View Abstract
  40. Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 Jul; 52(7):748-749. View Abstract
  41. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 09; 585(7824):293-297. View Abstract
  42. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 07; 52(7):662-668. View Abstract
  43. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564. View Abstract
  44. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020 02; 26(2):181-187. View Abstract
  45. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020 02; 1(2):235-248. View Abstract
  46. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun. 2019 12 20; 10(1):5817. View Abstract
  47. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949. View Abstract
  48. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019 11 11; 36(5):528-544.e10. View Abstract
  49. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421. View Abstract
  50. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019 08 27; 28(9):2331-2344.e8. View Abstract
  51. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell. 2019 07 25; 178(3):521-535.e23. View Abstract
  52. Structural mechanism of synergistic activation of Aurora kinase B/C by phosphorylated INCENP. Nat Commun. 2019 07 18; 10(1):3166. View Abstract
  53. Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 Jul; 15(7):757. View Abstract
  54. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019 07; 15(7):681-689. View Abstract
  55. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508. View Abstract
  56. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019 04; 568(7753):551-556. View Abstract
  57. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019 02; 19(2):97-109. View Abstract
  58. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6. View Abstract
  59. Protection of tissue physicochemical properties using polyfunctional crosslinkers. Nat Biotechnol. 2018 Dec 17. View Abstract
  60. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun. 2018 12 14; 9(1):5315. View Abstract
  61. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018 11 02; 9(1):4610. View Abstract
  62. Retraction Note: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2018 09; 561(7723):420. View Abstract
  63. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer. FASEB J. 2019 02; 33(2):1644-1657. View Abstract
  64. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018 09; 50(9):1240-1246. View Abstract
  65. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330. View Abstract
  66. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292. View Abstract
  67. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291. View Abstract
  68. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690. View Abstract
  69. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. View Abstract
  70. A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. Cell Syst. 2018 Apr 25; 6(4):424-443.e7. View Abstract
  71. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018 03 05; 215(3):895-910. View Abstract
  72. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553. View Abstract
  73. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2017 12 11; 32(6):884. View Abstract
  74. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462. View Abstract
  75. A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay. Gigascience. 2017 12 01; 6(12):1-5. View Abstract
  76. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017 Nov 30; 171(6):1437-1452.e17. View Abstract
  77. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 2017 Nov; 15(11):e2003213. View Abstract
  78. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Syst. 2018 01 24; 6(1):13-24. View Abstract
  79. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324. View Abstract
  80. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec; 49(12):1779-1784. View Abstract
  81. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun. 2017 10 30; 8(1):1186. View Abstract
  82. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017 Nov; 49(11):1567-1575. View Abstract
  83. Erratum: The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nat Immunol. 2017 09 19; 18(10):1173. View Abstract
  84. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 09 15; 357(6356):1156-1160. View Abstract
  85. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct; 49(10):1476-1486. View Abstract
  86. Defining a Cancer Dependency Map. Cell. 2017 Jul 27; 170(3):564-576.e16. View Abstract
  87. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60. View Abstract
  88. High-throughput validation of ceRNA regulatory networks. BMC Genomics. 2017 05 30; 18(1):418. View Abstract
  89. The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection. Nat Immunol. 2017 Jul; 18(7):791-799. View Abstract
  90. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med. 2017 04 07; 23(4):405-408. View Abstract
  91. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017 Apr 11; 1(10):619-623. View Abstract
  92. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332). View Abstract
  93. LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature. 2017 03 30; 543(7647):681-686. View Abstract
  94. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017 Jan; 13(1):46-53. View Abstract
  95. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016 11 10; 539(7628):309-313. View Abstract
  96. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016 11 02; 8(363):363ra147. View Abstract
  97. 334 A Functional Screen Identifies miRNAs that Induce Radioresistance in Glioblastomas. Neurosurgery. 2016 Aug; 63 Suppl 1:197-8. View Abstract
  98. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathog. 2016 07; 12(7):e1005763. View Abstract
  99. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2016 08 08; 30(2):214-228. View Abstract
  100. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nat Commun. 2016 07 04; 7:12160. View Abstract
  101. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 Aug; 6(8):914-29. View Abstract
  102. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016 07; 6(7):714-26. View Abstract
  103. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016 Apr 11; 29(4):602-606. View Abstract
  104. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016 Apr; 34(4):419-23. View Abstract
  105. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11; 351(6278):1214-8. View Abstract
  106. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016 Feb 08; 29(2):214-28. View Abstract
  107. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016 Jan; 48(1):101. View Abstract
  108. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81. View Abstract
  109. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015 Nov; 47(11):1326-1333. View Abstract
  110. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A. 2015 Oct 06; 112(40):E5486-95. View Abstract
  111. Corrigendum: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2015 Oct 22; 526(7574):596. View Abstract
  112. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet. 2015 Jul; 16(7):373-4. View Abstract
  113. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44. View Abstract
  114. A Maltose-Binding Protein Fusion Construct Yields a Robust Crystallography Platform for MCL1. PLoS One. 2015; 10(4):e0125010. View Abstract
  115. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. View Abstract
  116. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep. 2015 Feb 10; 10(5):755-770. View Abstract
  117. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73. View Abstract
  118. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18661-6. View Abstract
  119. Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1). ACS Med Chem Lett. 2014 Dec 11; 5(12):1308-12. View Abstract
  120. Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044. View Abstract
  121. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035. View Abstract
  122. A functional screen identifies miRs that induce radioresistance in glioblastomas. Mol Cancer Res. 2014 Dec; 12(12):1767-78. View Abstract
  123. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov; 4(11):1326-41. View Abstract
  124. Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):10911-6. View Abstract
  125. A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug; 10(8):656-63. View Abstract
  126. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014 Jul; 42(Web Server issue):W449-60. View Abstract
  127. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84. View Abstract
  128. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 May 29; 123(22):e123-33. View Abstract
  129. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014 Apr; 59(4):1577-90. View Abstract
  130. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014 Jan 13; 25(1):91-101. View Abstract
  131. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501. View Abstract
  132. Multiplex cytological profiling assay to measure diverse cellular states. PLoS One. 2013; 8(12):e80999. View Abstract
  133. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4. View Abstract
  134. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol. 2013 Dec; 9(12):840-848. View Abstract
  135. CXCR4 pathway associated with family history of melanoma. Cancer Causes Control. 2014 Jan; 25(1):125-32. View Abstract
  136. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143):1238303. View Abstract
  137. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218. View Abstract
  138. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013 Jun 10; 23(6):826-38. View Abstract
  139. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77. View Abstract
  140. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013 May; 45(5):478-86. View Abstract
  141. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013 May; 144(5):1024-30. View Abstract
  142. Expression profiling of archival tumors for long-term health studies. Clin Cancer Res. 2012 Nov 15; 18(22):6136-46. View Abstract
  143. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012 Nov 07; 104(21):1673-9. View Abstract
  144. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72. View Abstract
  145. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 01; 18(21 Suppl):S1-100. View Abstract
  146. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. View Abstract
  147. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012 Aug; 122(8):2983-8. View Abstract
  148. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9. View Abstract
  149. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9. View Abstract
  150. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6. View Abstract
  151. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012 Apr 17; 21(4):547-62. View Abstract
  152. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7. View Abstract
  153. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3879-84. View Abstract
  154. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2860-5. View Abstract
  155. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506. View Abstract
  156. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012 Jul 19; 31(29):3397-408. View Abstract
  157. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J. 2011 Nov; 1(11):e40. View Abstract
  158. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25. View Abstract
  159. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011 Aug 28; 17(9):1086-93. View Abstract
  160. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60. View Abstract
  161. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011 Jul 13; 475(7355):231-4. View Abstract
  162. Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):11842-7. View Abstract
  163. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6. View Abstract
  164. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. View Abstract
  165. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011 May; 140(5):1618-28.e16. View Abstract
  166. The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20. View Abstract
  167. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73. View Abstract
  168. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A. 2011 Feb 15; 108(7):2873-8. View Abstract
  169. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011 Jan 21; 144(2):296-309. View Abstract
  170. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72. View Abstract
  171. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct 28; 116(17):3268-77. View Abstract
  172. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14229-34. View Abstract
  173. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12617-22. View Abstract
  174. Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010 May 24; 5(5):e10770. View Abstract
  175. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010 Apr 15; 24(8):837-52. View Abstract
  176. Counterpoint: Data first. Nature. 2010 Apr 01; 464(7289):679. View Abstract
  177. The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. Cancer Res. 2010 Apr 15; 70(8):3071-9. View Abstract
  178. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010 Mar 16; 3:8. View Abstract
  179. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. View Abstract
  180. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110. View Abstract
  181. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009 Dec 01; 23(23):2700-4. View Abstract
  182. Empirical Bayes analysis of quantitative proteomics experiments. PLoS One. 2009 Oct 14; 4(10):e7454. View Abstract
  183. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94. View Abstract
  184. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009 Sep 15; 23(18):2152-65. View Abstract
  185. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009 Sep 15; 69(18):7385-92. View Abstract
  186. microRNA expression during trophectoderm specification. PLoS One. 2009 Jul 03; 4(7):e6143. View Abstract
  187. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8. View Abstract
  188. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol. 2009 May 20; 27(15_suppl):9003. View Abstract
  189. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205. View Abstract
  190. Prolonged therapy for hepatitis C with low-dose peginterferon. N Engl J Med. 2009 Mar 12; 360(11):1152; author reply 1152-3. View Abstract
  191. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4617-22. View Abstract
  192. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009 Apr; 29(8):2193-204. View Abstract
  193. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell. 2008 Dec 26; 32(6):838-48. View Abstract
  194. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009 Jan; 27(1):77-83. View Abstract
  195. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5. View Abstract
  196. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008 Nov 06; 359(19):1995-2004. View Abstract
  197. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008 Oct 07; 105(40):15535-40. View Abstract
  198. Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J Immunol. 2008 Aug 01; 181(3):1859-68. View Abstract
  199. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug; 14(8):822-7. View Abstract
  200. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008 Jul 15; 105(28):9751-6. View Abstract
  201. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res. 2008 Jul 01; 68(13):5040-8. View Abstract
  202. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood. 2008 Sep 01; 112(5):1981-92. View Abstract
  203. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008 Jun; 14(6):843-53. View Abstract
  204. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008 Jun 04; 100(11):815-25. View Abstract
  205. Gene expression-based screening for inhibitors of PDGFR signaling. Genome Biol. 2008; 9(3):R47. View Abstract
  206. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol. 2008 Mar; 26(3):343-51. View Abstract
  207. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73. View Abstract
  208. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008 Feb; 5(2):e35. View Abstract
  209. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008 Jan 17; 451(7176):335-9. View Abstract
  210. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12. View Abstract
  211. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19971-6. View Abstract
  212. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13. View Abstract
  213. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One. 2007 Nov 21; 2(11):e1195. View Abstract
  214. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A. 2007 Nov 06; 104(45):17771-6. View Abstract
  215. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science. 2007 Sep 14; 317(5844):1500. View Abstract
  216. Altered microRNA expression in human heart disease. Physiol Genomics. 2007 Nov 14; 31(3):367-73. View Abstract
  217. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008 Jan 10; 27(3):318-22. View Abstract
  218. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007 Oct 15; 110(8):3015-27. View Abstract
  219. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007 Jun; 11(6):555-69. View Abstract
  220. Genomics: global views of leukaemia. Nature. 2007 Apr 12; 446(7137):739-40. View Abstract
  221. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007 May; 39(5):673-7. View Abstract
  222. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007 Apr; 4(4):e122. View Abstract
  223. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 2007 Feb; 9(1):20-9. View Abstract
  224. IFN-alpha-stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas. Cancer Res. 2007 Jan 15; 67(2):474-81. View Abstract
  225. Prospective isolation and global gene expression analysis of definitive and visceral endoderm. Dev Biol. 2007 Apr 15; 304(2):541-55. View Abstract
  226. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98. View Abstract
  227. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006 Sep 29; 313(5795):1929-35. View Abstract
  228. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct; 10(4):331-42. View Abstract
  229. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct; 10(4):321-30. View Abstract
  230. Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. Biochem Biophys Res Commun. 2006 Sep 22; 348(2):628-36. View Abstract
  231. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22. View Abstract
  232. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul; 3(7):e270. View Abstract
  233. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006 May; 9(5):405-16. View Abstract
  234. Celastrol, Gedunin, and Derivatives Thereof as Hsp90 Inhinitors. 2006. View Abstract
  235. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006 Mar 01; 66(5):2815-25. View Abstract
  236. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3339-44. View Abstract
  237. Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol. 2006 Feb; 26(3):1109-23. View Abstract
  238. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 01; 12(1):152-8. View Abstract
  239. A method for high-throughput gene expression signature analysis. Genome Biol. 2006; 7(7):R61. View Abstract
  240. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol. 2005 Dec; 79(24):15430-42. View Abstract
  241. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006 Jan 19; 439(7074):358-62. View Abstract
  242. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15545-50. View Abstract
  243. A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13194-9. View Abstract
  244. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22. View Abstract
  245. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005 Oct 15; 106(8):2841-8. View Abstract
  246. MicroRNA expression profiles classify human cancers. Nature. 2005 Jun 09; 435(7043):834-8. View Abstract
  247. Solution-based methods for RNA expression profiling. 2005. View Abstract
  248. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9. View Abstract
  249. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol. 2005 May; 173(5):1772-7. View Abstract
  250. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97. View Abstract
  251. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood. 2005 Jun 15; 105(12):4620-6. View Abstract
  252. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature. 2005 Mar 17; 434(7031):338-45. View Abstract
  253. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005 Jan 26; 24(2):368-81. View Abstract
  254. Acute Myeloid Leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2005; 20:545-589. View Abstract
  255. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005 Jan; 37(1):48-55. View Abstract
  256. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75. View Abstract
  257. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004 Dec; 6(6):565-76. View Abstract
  258. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005 Mar 01; 105(5):1851-61. View Abstract
  259. Toward a functional taxonomy of cancer. Cancer Cell. 2004 Aug; 6(2):107-8. View Abstract
  260. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res. 2004 Jun 15; 64(12):4137-47. View Abstract
  261. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 Jun; 10(6):594-601. View Abstract
  262. Genomic approaches to hematologic malignancies. Blood. 2004 Aug 15; 104(4):923-32. View Abstract
  263. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004 Apr 27; 101(17):6478-83. View Abstract
  264. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004 Mar 23; 101(12):4164-9. View Abstract
  265. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet. 2004 Mar; 36(3):257-63. View Abstract
  266. MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol. 2003 Oct; 40(4):268-73. View Abstract
  267. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 01; 102(12):3871-9. View Abstract
  268. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003 Aug 08; 114(3):323-34. View Abstract
  269. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003 Jul; 34(3):267-73. View Abstract
  270. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A. 2003 Jun 24; 100(13):7841-6. View Abstract
  271. Mining the genome for combination therapies. Nat Med. 2003 May; 9(5):510-1. View Abstract
  272. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7. View Abstract
  273. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83. View Abstract
  274. Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol. 2003; 10(2):119-42. View Abstract
  275. The Molecular Basis of Hematologic Malignancy. Nathan DG, Oski SH, eds. Nathan and Oski’s Hematology of Infancy and Childhood. 2003; 2:1219-1258. View Abstract
  276. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003 Jan; 33(1):49-54. View Abstract
  277. A strategy for oligonucleotide microarray probe reduction. Genome Biol. 2002; 3(12):RESEARCH0073. View Abstract
  278. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15468-73. View Abstract
  279. Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol. 2002 Nov; 22(21):7439-48. View Abstract
  280. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002 Nov; 51(11):3176-88. View Abstract
  281. Abnormal gene expression in cloned mice derived from embryonic stem cell and cumulus cell nuclei. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):12889-94. View Abstract
  282. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol. 2002 Aug; 22(15):5575-84. View Abstract
  283. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002 Jun 14; 109(6):707-18. View Abstract
  284. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 2002 May; 1(4):393-401. View Abstract
  285. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes. 2002 May; 51(5):1319-36. View Abstract
  286. DNA microarrays in clinical oncology. J Clin Oncol. 2002 Apr 01; 20(7):1932-41. View Abstract
  287. DNA Microarrays in Clinical Oncology. Journal of Clinical Oncology. 2002; 20(7):1932-41. View Abstract
  288. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3806-11. View Abstract
  289. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar; 1(2):203-9. View Abstract
  290. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002 Feb; 1(1):75-87. View Abstract
  291. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24; 415(6870):436-42. View Abstract
  292. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002 Jan; 8(1):68-74. View Abstract
  293. Acute Myeloid Leukemia. Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2002; 20:545-589. View Abstract
  294. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001 Dec 18; 98(26):15149-54. View Abstract
  295. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7. View Abstract
  296. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5. View Abstract
  297. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10787-92. View Abstract
  298. Genomic approaches to the pathogenesis of hematologic malignancy. Curr Opin Hematol. 2001 Jul; 8(4):252-61. View Abstract
  299. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 2001 Jun; 21(11):3789-806. View Abstract
  300. Genome-wide views of cancer. N Engl J Med. 2001 Feb 22; 344(8):601-2. View Abstract
  301. Molecular classification of multiple tumor types. Bioinformatics. 2001; 17 Suppl 1:S316-22. View Abstract
  302. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12182-6. View Abstract
  303. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000 Aug 03; 406(6795):532-5. View Abstract
  304. GAP43, MARCKS, and CAP23 modulate PI(4,5)P(2) at plasmalemmal rafts, and regulate cell cortex actin dynamics through a common mechanism. J Cell Biol. 2000 Jun 26; 149(7):1455-72. View Abstract
  305. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3260-5. View Abstract
  306. TEL/ETV6 Gene Rearrangements in Human Leukemias. Transcription Factors: Normal and Malignant Development of Blood Cells. 2000; 425-445. View Abstract
  307. Molecular Biology. Holland, James F. and Frei, Emil III, eds. Cancer Medicine. 2000; 1-16. View Abstract
  308. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15; 286(5439):531-7. View Abstract
  309. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2907-12. View Abstract
  310. Methods and Apparatus for Analyzing Gene Expression Data. 1999. View Abstract
  311. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998 Dec 15; 92(12):4792-7. View Abstract
  312. Dissecting the regulatory circuitry of a eukaryotic genome. Cell. 1998 Nov 25; 95(5):717-28. View Abstract
  313. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 1998 Aug 01; 12(15):2392-402. View Abstract
  314. The Molecular Biology of Cancer. Nathan and Oski’s Hematology of Infancy and Childhood. 1998; 2:1092-1146. View Abstract
  315. TEL gene rearrangements in myeloid malignancy. Hematol Oncol Clin North Am. 1997 Dec; 11(6):1207-20. View Abstract
  316. TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia. 1997 Aug; 11(8):1220-3. View Abstract
  317. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 1997 Jul 16; 16(14):4374-83. View Abstract
  318. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia. 1997 Mar; 11(3):441-7. View Abstract
  319. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 1997; 220:67-79. View Abstract
  320. Acute Myelogenous Leukemia. Principles and Practice of Pediatric Oncology. 1997; 463-482. View Abstract
  321. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996 Dec 10; 93(25):14845-50. View Abstract
  322. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8. View Abstract
  323. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996 Sep 19; 13(6):1147-52. View Abstract
  324. The TEL gene and human leukemia. Biochim Biophys Acta. 1996 Aug 08; 1288(1):M7-10. View Abstract
  325. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996 Aug; 16(8):4107-16. View Abstract
  326. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol. 1996 Apr; 16(4):1349-55. View Abstract
  327. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res. 1996 Mar 15; 56(6):1413-7. View Abstract
  328. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 1996; 211:279-88. View Abstract
  329. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood. 1995 Aug 15; 86(4):1525-33. View Abstract
  330. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995 May 23; 92(11):4917-21. View Abstract
  331. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994 Apr 22; 77(2):307-16. View Abstract
  332. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol. 1991 May; 65(5):2254-60. View Abstract
  333. In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene. 1990 Apr; 5(4):571-6. View Abstract
  334. Growth and characterization of epithelial cells from normal human uterine ectocervix and endocervix. In Vitro Cell Dev Biol. 1989 Jun; 25(6):544-56. View Abstract

Contact Todd Golub

Print Profile